How Is Cardiex Driving Pulse Sales and Subscription Growth in FY25?

Strong Sales Momentum for Pulse

Cardiex has demonstrated robust growth in sales of its CONNEQT Pulse arterial health monitor throughout the June 2025 quarter, with FY25 sales surpassing A$0.7 million and total units sold exceeding 2,100. The device’s direct-to-consumer eCommerce channel showed particularly strong traction, more than doubling sales quarter-over-quarter. While the company initially targeted rapid volume growth, it has since shifted focus to optimizing marketing strategies and customer acquisition costs to ensure sustainable, long-term expansion.

Clinician and Consumer Validation

Feedback from both healthcare professionals and consumers has been overwhelmingly positive. Cardiologists are actively integrating Pulse data into treatment plans, appreciating its clinical-grade insights and usability. Patients value the empowerment gained from on-demand cardiovascular assessments at home, which complement traditional clinical visits. However, some users have raised concerns about pricing and device features such as charging standards and multi-user support, highlighting areas for future product refinement.

Digital Health and Subscription Transition

Cardiex launched an On-Demand Cardiovascular Assessment feature within its CONNEQT App, enabling users to generate comprehensive, physician-style cardiology reports instantly. This innovation is central to the company’s strategic pivot toward subscription-based digital health services, aiming to lower upfront device costs and create recurring revenue streams. Parallel development is underway to introduce the same cardiology report on the SphygmoCor XCEL platform, targeting clinical markets with a usage-based subscription model expected to roll out in Q2 FY26.

Regulatory and Market Expansion

The Pulse arterial health monitor received inclusion in the Australian Register of Therapeutic Goods (ARTG) in June 2025, clearing the path for commercialization in Australia. Cardiex is leveraging this approval to explore opportunities in pharmaceutical, research, and clinical sectors. The company also participated in several high-profile industry events, including presentations of validation studies confirming the Pulse’s alignment with gold-standard clinical measures, further bolstering its credibility.

Financial Position and Capital Raising

Cardiex completed a $6.5 million capital raise during the quarter through an institutional placement and a fully underwritten entitlement offer, with participation from existing and new investors including C2 Ventures Pty Ltd. The funds will support manufacturing, marketing, and commercial expansion efforts. The company ended the quarter with $2.43 million in cash and expects an additional $1.2 million in early FY26, positioning it to execute its growth strategy amid ongoing operational streamlining and cost management.